SPY 120
Alternative Names: PR-022 - Spyre Therapeutics; SPY-120Latest Information Update: 07 Mar 2024
At a glance
- Originator Paragon Therapeutics
- Developer Paragon Therapeutics; Spyre Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Alpha4beta7 integrin antagonists; Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases